Alzamend Neuro Balance Sheet

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Cash & Equivalents	0.71	3.95	0.38	5.14	14.06
Cash & Short-Term Investments	0.71	3.95	0.38	5.14	14.06
Cash Growth	-82.00%	950.04%	-92.69%	-63.45%	628.97%
Other Current Assets	1.05	0.23	0.08	0.69	0.35
Total Current Assets	1.76	4.18	0.46	5.84	14.41
Net Property, Plant & Equipment	0.31	0.43	0.18	0.08	0.1
Total Assets	2.08	4.6	0.63	5.92	14.52
Accounts Payable	1.35	0.63	2.93	2.87	1.16
Short-Term Debt	-	-	0.3	-	-
Other Current Liabilities	-	-	-	-	0
Total Current Liabilities	1.35	0.63	3.23	2.87	1.16
Total Liabilities	1.35	0.63	3.23	2.87	1.16
Common Stock	0	0	0	0	0.01
Treasury Stock	-	-	-	-14.88	-14.88
Additional Paid-in Capital	68.04	62.5	51.43	62	57.42
Retained Earnings	-67.31	-58.54	-54.02	-44.07	-29.19
Shareholders' Equity	0.73	3.97	-2.59	3.05	13.35
Total Liabilities & Equity	2.08	4.6	0.63	5.92	14.52
Total Debt	0	0	0.3	0	0
Net Cash (Debt)	0.71	3.95	0.08	5.14	14.06
Net Cash Growth	-82.00%	5141.53%	-98.53%	-63.45%	782.32%
Net Cash Per Share	0.21	8.76	1.02	71.17	213.10
Book Value	0.73	3.97	-2.59	3.05	13.35
Book Value Per Share	0.22	8.80	-34.97	42.16	202.31
Tangible Book Value	0.73	3.97	-2.59	3.05	13.35
Tangible Book Value Per Share	0.22	8.80	-34.97	42.16	202.31

SEC Filings: 10-K · 10-Q